Company Overview - Dongbao Biological (SZ 300239) announced the convening of its 14th meeting of the 9th Board of Directors on October 28, 2025, to review the proposal for the "2025 Third Quarter Report" [1] - The company's revenue composition for the year 2024 is entirely from biological and biochemical products, accounting for 100.0% [1] - As of the report, Dongbao Biological has a market capitalization of 3.4 billion yuan [1] Industry Context - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - This shift indicates the emergence of a "slow bull" market pattern, suggesting a new phase in market dynamics [1]

第九届董事会第十四次会议决议公告 包头东宝生物技术股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-067 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 2025 年第三季度报告的内容真实、准确、完整地反映了公司 2025 年第三季 度的实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏，报告的编制 和审核程序符合法律、行政法规的要求，符合中国证监会和深交所的相关规定。 公司董事会同意议案内容。 表决结果：7 票同意，0 票反对，0 票弃权。 本议案获得表决通过。公司第九届董事会审计委员会审议通过了本议案。具 体内容详见同日披露于巨潮资讯网的《2025 年第三季度报告》(2025-068)。 三、备查文件 1、第九届董事会第十四次会议决议； 2、深圳证券交易所要求的其他文件。 特此公告。 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十四次 会议 ...

Financial Performance - The company's revenue for Q3 2025 was ¥163,742,176.20, a decrease of 13.29% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥11,482,207.82, down 23.10% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥8,620,812.63, reflecting a decline of 34.37% compared to the previous year[10]. - Total operating revenue for the current period was ¥532,797,977.19, a decrease of approximately 16% compared to ¥633,112,065.92 in the previous period[25]. - Net profit for the current period is 48,447,635.50, a decrease of 32.3% compared to 71,535,188.56 in the previous period[26]. - Operating profit for the current period is 55,378,873.91, down from 82,596,541.20, reflecting a decline of 33.0%[26]. - Total comprehensive income for the current period is 48,447,635.50, down 32.3% from 71,535,188.56 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,543,840,091.48, a decrease of 3.09% from the end of the previous year[5]. - Total liabilities decreased to ¥826,649,536.43 from ¥885,496,289.52, a decline of about 6.6%[24]. - The total assets decreased to ¥2,543,840,091.48 from ¥2,624,919,556.21, reflecting a reduction of about 3.1%[24]. - Long-term equity investments decreased to ¥13,914,675.17 from ¥15,428,520.01, a decline of approximately 9.8%[23]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥61,417,693.72, an increase of 109.82%[5]. - The net cash flow from operating activities increased to ¥61,417,693.72, a rise of 109.82% compared to the previous period's ¥29,272,022.08, primarily due to higher cash received from sales[14]. - Cash flow from operating activities increased to 61,417,693.72, compared to 29,272,022.08 in the previous period, representing a growth of 109.5%[27]. - Cash flow from investing activities resulted in a net outflow of -42,377,549.85, an improvement from -134,567,469.44 in the previous period[28]. - Cash flow from financing activities was -¥18,959,353.05, with a significant increase of 263.36% from the previous period, attributed to higher cash payments for debt repayment and dividends, along with stock buyback activities[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,471, with no preferred shareholders having restored voting rights[16]. - Qingdao Guoen Technology Co., Ltd. held the largest share, owning 21.18% (125,711,022 shares) of the company[16]. - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 21.18% and the smallest in the top ten holding 0.62%[16]. - The company has a repurchase account holding 10,573,400 shares, representing 1.78% of the total share capital[17]. - There were no changes in the number of preferred shareholders or significant changes in the top ten shareholders due to lending or borrowing of shares[18]. - The company reported a total of 3,962,437 restricted shares, with 116,287 shares released during the period[19]. Operating Costs and Expenses - Total operating costs decreased to ¥479,925,097.45 from ¥555,269,833.32, reflecting a reduction of about 13.5%[25]. - The company's net profit margin is under pressure due to increased operating expenses, with research and development expenses rising to ¥18,907,749.32 from ¥16,012,452.92, an increase of about 18%[25]. - Financial expenses increased by 130.70% to ¥1,137,785.38, primarily due to higher interest expenses[11]. Inventory and Receivables - Accounts receivable decreased to ¥173,096,032.96 from ¥206,201,924.73, representing a reduction of about 16%[22]. - Inventory increased significantly to ¥420,415,267.14 from ¥354,463,939.10, an increase of approximately 18.6%[22]. - The company's cash and cash equivalents decreased to ¥483,228,383.16 from ¥532,101,881.48, a decline of approximately 9.2%[22]. - The company reported a decrease in total assets impairment losses to -4,747,143.37 from -1,548,347.56, indicating a significant change in asset valuation[26].

Core Viewpoint - Dongbao Biological (300239) clarified on October 24 that its gelatin products are not used in breast enhancement applications [1] Company Summary - Dongbao Biological responded to investor inquiries on an interactive platform regarding the use of its gelatin products [1]

Core Viewpoint - Dongbao Bio has confirmed that its artificial blood plasma gelatin has achieved sales, indicating progress in its product development and market entry [2] Company Summary - Dongbao Bio (300239.SZ) responded to an investor inquiry on October 24, stating that its artificial blood plasma gelatin (Pharmacopoeia gelatin) is now available for sale [2]

Group 1 - The artificial meat concept sector rose by 1.81%, ranking fifth among concept sectors, with 14 stocks increasing in value, including Shuangta Food, which hit the daily limit, and others like Suobao Protein and Haoxiangni showing gains of 6.33%, 3.53%, and 2.66% respectively [1][2] - The main inflow of funds into the artificial meat concept sector was 132 million yuan, with Shuangta Food receiving the highest net inflow of 98.69 million yuan, followed by Suobao Protein and Meiyingsen with net inflows of 46.11 million yuan and 16.86 million yuan respectively [2][3] - The net inflow ratios for Shuangta Food, Suobao Protein, and Meiyingsen were 31.69%, 11.94%, and 8.56% respectively, indicating strong investor interest in these stocks [3] Group 2 - Among the stocks in the artificial meat sector, the top performers included Shuangta Food with a daily increase of 9.98% and a turnover rate of 4.40%, while stocks like Haoxiangni and Dongbao Biological also showed positive performance with increases of 3.53% and 2.66% respectively [3][4] - Conversely, stocks such as Angel Yeast, Fuxiang Pharmaceutical, and Tangrenshen experienced declines of 0.91%, 0.57%, and 0.21% respectively, indicating mixed performance within the sector [1][4]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Group 1 - The core viewpoint of the article highlights the active performance of plant-based meat concept stocks in the A-share market, with notable gains in companies like SuoBao Protein and Shuangta Food reaching the daily limit, while Dongbao Bio and Hao Xiang Ni also saw significant increases [1] - Beyond Meat, the first plant-based meat stock in the US market, experienced a dramatic surge, with a 127% increase on Monday followed by a further 146.26% rise on Tuesday, resulting in a total price increase of over 450% in just two trading days [1]

Core Viewpoint - Dongbao Biological announced that it will not adjust the conversion price of its convertible bonds despite triggering conditions for a downward adjustment due to stock prices being below 90% of the conversion price for 15 trading days [1] Group 1: Company Actions - The company’s stock price has been below the conversion price of 6.63 yuan per share for 15 trading days, triggering the conditions for a downward adjustment of the "Dongbao Convertible Bonds" [1] - The board of directors held a meeting on October 15, 2025, and decided not to adjust the conversion price of the "Dongbao Convertible Bonds" [1] - From October 16, 2025, to April 15, 2026, if the conditions for a downward adjustment are triggered again, the company will not propose a downward adjustment plan [1] Group 2: Future Considerations - After April 16, 2026, if the conditions for a downward adjustment are triggered again, the board will convene to decide whether to exercise the right to adjust the conversion price [1]

Group 1 - The company Dongbao Biological announced that its 13th meeting of the 9th board of directors will be held on October 15, 2025, at its headquarters in Baotou [1] - The meeting will review the proposal regarding not adjusting the conversion price of "Dongbao Convertible Bonds" [1]